Cite
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
MLA
Liu, Glenn, et al. “An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 15, no. 9, May 2009, pp. 3172–76. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-08-2985.
APA
Liu, G., Kelly, W. K., Wilding, G., Leopold, L., Brill, K., & Somer, B. (2009). An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 15(9), 3172–3176. https://doi.org/10.1158/1078-0432.CCR-08-2985
Chicago
Liu, Glenn, W Kevin Kelly, George Wilding, Lance Leopold, Kimberli Brill, and Bradley Somer. 2009. “An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 15 (9): 3172–76. doi:10.1158/1078-0432.CCR-08-2985.